期刊
CANCER LETTERS
卷 275, 期 1, 页码 86-92出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2008.10.001
关键词
Prostate cancer; LNCaP; EGCG; PSA; Androgen receptor
类别
资金
- US National Institute of Health [CA58073, AT00850]
- National Science Council of Taiwan [NSC-096-2917-1-564-103]
The green tea polyphenol, (-)-epigallocatechin-3-gallate (EGCG), inhibits the development and progression of prostate cancer in TRAMP mice and in men. We examined the effects of EGCG on LNCaP human prostate cancer sublines 104-S, 104-R1 and R1Ad representing different progression stages of prostate cancer. EGCG suppressed cell proliferation, prostate specific antigen (PSA) expression, and AR transcriptional activity in the different LNCaP sublines. Intraperitoneal administration of EGCG also suppressed the growth of relapsing R1Ad tumors and decreased tumor-derived serum PSA. Effects of EGCG on tumor PSA expression have the potential to affect accurate monitoring of patient tumor burden by serum PSA measurements. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据